Corcept Therapeutics Incorporated
corporate_fare Company Profile
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CORT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CORT spans 10-Q, 8-K, DEF 14A.
Recent high-impact activity:
- Corcept 10-Q: Q3 Revenue $340.5M, Net Income $126.8M, Buyback Nearly Exhausted
- Q3 Revenue Jumps 64% to $340.5M as Lifyorli Launch Accelerates; Guidance Reiterated
- BELLA Triplet Data Show 7.2-Month PFS in Platinum-Resistant Ovarian Cancer
- ADA/EASD Guidelines Back T2D Screening for Hypercortisolism, Citing Corcept's Mifepristone Data
- CHMP Backs EU Approval for Corcept's Lifyorli in Ovarian Cancer
Financial Snapshot
Short Interest & Short Volume
8.10 days to coverFINRA reported short interest of 9,125,717 shares in CORT as of the October 30, 2026 settlement, a 6.3% increase from the prior period — about 8.1 days to cover at its recent average daily volume. On November 20, 2026, 56.4% of CORT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CORT, detected from its recent SEC filings · based on capital-structure filings through 2026-05-28.
Incentive Plan Share Increase Approved · Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →